Efficacy of bevacizumab versus epidermal growth factor receptor inhibitors for wild-type RAS metastatic colorectal cancer: a meta-analysis

BACKGROUND: Results from several prospective clinical trials comparing anti-epidermal growth factor receptor (EGFR) therapy and anti-vascular endothelial growth factor (VEGF) therapy plus chemotherapy for wild-type RAS metastatic colorectal cancer (mCRC) have been inconsistent. This meta-analysis ai...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Wei, Yu, Qitao, Ning, Ruiling, Zhao, Wenhua, Wei, Changyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6065471/
https://www.ncbi.nlm.nih.gov/pubmed/30100734
http://dx.doi.org/10.2147/OTT.S168695

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6065471/
https://www.ncbi.nlm.nih.gov/pubmed/30100734
http://dx.doi.org/10.2147/OTT.S168695

Ejemplares similares